Navigation Links
eClinical Solutions Teams with Karyopharm for COVID-19 Treatment Trial
Date:6/25/2020

eClinical Solutions LLC, a leading global provider of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI) on randomized clinical trials for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first study of an XPO1 inhibitor in patients with severe viral infections. XPO1 inhibitors like selinexor (marketed as XPOVIO®) have previously shown preclinical activity against respiratory viruses, including SARS-CoV.

“The eClinical Solutions team is extremely motivated by the opportunity to contribute to finding new therapies that may treat COVID-19,” said Raj Indupuri, CEO of eClinical Solutions. “We are proud to partner with Karyopharm to support rapid data collection, cleaning and review for this program. The way they use modern technologies in clinical research to optimize data collection and analysis demonstrates their dedication to innovation not only in scientific research, but throughout the clinical development process.”

The eClinical Solutions Data Services team configured the data capture system for the trial using Medidata Rave EDC and the elluminate Clinical Data Platform for agile data management and review. The Karyopharm and eClinical Solutions teams collaborated closely to build a fully validated data database to collect data from physicians and patients in just 15 days—an accelerated timeline in order to meet the first patient milestone of this critical research initiative. The eClinical Solutions data management team is using elluminate Data Central to support data review activities for the study to ensure data is rapidly cleaned and available for medical and safety review.

“eClinical Solutions has been a valuable partner on other selinexor research programs. Their team’s knowledge of Karyopharm data standards and processes combined with their expertise in data collection platforms and clinical data management practices helped us meet our accelerated timelines for this important new research,” said Kristan Gallitano, SVP Development Operations at Karyopharm Therapeutics.

About eClinical Solutions
eClinical Solutions is a leading global provider of cloud-based enterprise software and software-driven clinical data services. The elluminate® platform provides life sciences companies with greater control of their clinical trial data. elluminate software and data-driven services have been used by more than 100 life sciences companies on more than 1000 trials. eClinical Solutions has worked with Karyopharm since 2015 to tech-enable a simplified data flow and help produce high quality data for more than 10 studies, including 5 database locks that provided the data for the July 2019 FDA approval of Karyopharm's lead compound XPOVIO® (selinexor). Learn more about eClinical Solutions and Karyopharm in this Case Study. For more information visit eclinicalsol.com.

About Karyopharm Therapeutics, Inc.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit http://www.karyopharm.com.

Read the full story at https://www.prweb.com/releases/eclinical_solutions_teams_with_karyopharm_for_covid_19_treatment_trial/prweb17214370.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. StageBio and Alizée Pathology join forces to meet the growing demand for high-quality histopathology and medical device services in the preclinical services market
2. Quartesian LLC Executes Multi-Year Enterprise Agreement with Medrio, Securing Access to Innovative eClinical Functionality and Support Services
3. Avastus Opens New Vivarium to Serve the Preclinical Research Needs of Boston’s Biotech Community
4. MedNet Solutions Announces Latest Release Of Its Award-Winning eClinical Solution
5. MedNet Solutions Named Most Outstanding eClinical Solutions Company
6. Clinlogix Strengthens Partnership With eClinical Technology Leader MedNet Solutions
7. MedNet Solutions iMedNet eClinical Wins Silver Stevie Award
8. Sponsors And CROs Rapidly Adopting MedNet Solutions eClinical Technology Platform
9. Quadrapeutics works in preclinical study of hard-to-treat tumors
10. MedNet Solutions Announces Latest Release Of Its Innovative iMedNet EDC eClinical Solution
11. Inflection Biosciences licenses preclinical oncology programs from the CNIO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2020)... ... June 02, 2020 , ... ... and solutions provider, today reported that the implementation of browser-based, enterprise label ... 100%, resulting in greater efficiency for global biotechnology company, bioMérieux. , Headquartered ...
(Date:5/28/2020)... and FORT WORTH, Texas (PRWEB) , ... May ... ... stage biopharmaceutical company, announced today that interim results from their 1801 Phase 1/2 ... of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on May ...
(Date:5/21/2020)... ... May 20, 2020 , ... ... for drugs, biologics, cell and gene therapies, and consumer health products, today announced ... will be presenting at the ISCT 2020 Paris Virtual conference, which takes place ...
Breaking Biology News(10 mins):
(Date:6/19/2020)... Russia (PRWEB) , ... June 18, 2020 , ... The ... 2018. Its goal is to join forces to radically prolong life and find a ... postpone the aging period. This project was supported by various scientists from all over ...
(Date:6/11/2020)... ... June 09, 2020 , ... Reducing carbon emissions has been ... the Paris Agreement to stock market dips, ways to reduce CO2 is something we ... their portfolio. Most of the biofuels being produced today are created from recycled cooking ...
(Date:5/30/2020)... ... May 29, 2020 , ... ... 360°, the first newsletter solely dedicated to the unique role of the Chief ... of perspectives on the responsibilities, problem-solving, best practices and career development of CMOs ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... ... of clinical trials will cause long-term harm , Contrary to conventional wisdom that ... Institute study finds many companies will emerge from the pandemic commercially weaker, ...
Breaking Biology Technology: